Newsroom

Absci 21h ago

We'll be at the 35th European Academy of Dermatology and Venereology (#EADV2026) Congress in Vienna! Join us September 30 – October 3 at the Austria Center Vienna, where we'll share more about our internal pipeline program for pattern hair loss. ABS-201 is a novel, AI-designed monoclonal antibody currently being evaluated in the Phase 1/2a HEADLINE Clinical Trial. Poster: Prolactin Receptor Antagonism by ABS-201 Drives Hair Follicle Growth and Stem/Progenitor Cell Expansion in Human Male Scalp Skin

View post on LinkedIn

Absci 6d ago

At Absci, we're working to make the impossible a reality. ✨ If you're ready to make an impact and advance our pipeline of AI-designed antibodies, join us. We are currently hiring for several open roles across AI Research & Engineering, Clinical Research & Operations, and Regulatory & Quality: • Senior/Staff AI Scientist, Antibody Design • Senior/Staff AI Scientist, Target Discovery • Senior Director, Inspection Readiness • Director, Regulatory & Compliance • Sr. Manager, Quality • Clinical Trial Manager Apply today to join our mission: creating better biologics for patients, faster, while shaping the future of medicine.https://https://lnkd.in/gR8pdj7h

View post on LinkedIn

Absci 1w ago

Absci Founder & CEO Sean McClain recently sat down for a podcast interview with hair science educator Rob English, where they break down the potentially regenerative mechanism behind ABS-201 for pattern hair loss. In this video, Sean unpacks the novel science and clinical progress behind ABS-201, our AI-designed antibody in Phase 1/2a clinical trials for pattern hair loss. Watch the interview to see how ABS-201 was engineered to target key biological pathways involved in hair follicle miniaturization. Watch the full interview: https://lnkd.in/gaFiVR-x

View post on LinkedIn